Sirexatamab + chemo/bev shows 35% ORR in CRC (vs 23% control); gastric trial fails to advance to Phase 3

CYPHERPUNK TECHNOLOGIES INC.

Part B DeFianCe (n=188): sirexatamab arm ORR 35% vs control 23%; DCR 86% vs 84%.
Left-sided tumors ORR 38% (experimental) vs 25% (control); DKK1-high upper quartile ORR 48% vs 11%.
PFS not yet mature; 82 patients still on study. Leap plans registrational Phase 3 in CRC subject to regulatory discussions.
Part C DisTinGuish gastric: no clear positive signal; primary PFS endpoints will be negative; no Phase 3 plans for gastric.
Gastric study showed high discordance between investigator and BICR; sirexatamab combo well-tolerated in both studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.